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Interleukin-6, interleukin-8 and monocyte chemotactic peptide-1
gene expression and protein synthesis are independently modu-
lated by hemodialysis membranes.
Background. Uremia produces a wide range of abnormalities of
the immune system. Blood-membrane interaction in hemodialysis
results in activation and severe dysfunction of peripheral blood
mononuclear cells (PBMC). However, the question of whether
the use of different dialytic membranes may improve PBMC
dysfunctions remains unanswered.
Methods. To address this issue, the spontaneous interleukin
(IL)-6, IL-8 and monocyte chemotactic peptide-1 (MCP-1) gene
expression and protein release were studied in PBMC isolated
from 7 healthy subjects, 8 uremic patients on conservative therapy
and 8 uremic patients undergoing subsequent one month periods
of hemodialysis with cuprophan (CU) and high-flux noncomple-
ment activating membranes, polymethylmethacrylate (PMMA)
and polyamide (PA). At the end of each period of treatment,
PBMC were harvested at the beginning (T0) and after 180
minutes of dialysis (T180), and then were cultured in complete
medium. IL-6, IL-8 and MCP-1 mRNA expression were studied
by RT-PCR. In addition, MCP-1 gene expression was evaluated
also by in situ hybridization. Cytokines released in the supernatant
were measured by ELISA.
Results. Compared to the control group, PBMC from uremic
patients on conservative therapy and treated by CU showed a
clear reduction in the cytokine release, while PMMA and PA
membranes were able to normalize IL-6, IL-8 and MCP-1 protein
concentration, which had been reduced by CU treatment. Inter-
estingly, at T0, mRNA expression for all three cytokines was
increased in the patients treated by CU, when compared to the
control group and the uremic patients on conservative therapy. A
further up-regulation was observed at T180. PMMA and PA
treatment, despite increasing the cytokine secretion, significantly
reduced the dialysis-induced cytokine gene expression.
Conclusion. PBMC exposure to CU membranes results in
cytokine mRNA overexpression associated with a paradoxically
reduced protein release. In contrast, long-term hemodialysis with
synthetic high-flux membranes reduces IL-6, IL-8 and MCP-1
gene expression and improves the ability of PBMC to secrete
these cytokines. The reduced cytokine secretion during bioincom-
patible dialysis may reflect a PBMC adaptation that protects
uremic patients against the inflammatory effects of persistent
cytokine release.
Chronic renal failure per se induces a clinical state of
immunodeficiency that is exacerbated by hemodialysis in-
dependently of the membrane used [1]. Indeed, hemodia-
lyzed patients show clinical evidence of impaired immune
response, such as prolonged skin graft survival [2], de-
creased skin test reactivity [3] and impaired response to
hepatitis B vaccine [4], likely due to a defective B cell
response [5] and to an altered monocyte, natural killer or
polymorphonuclear cell function [6–8]. As a consequence
of this altered condition of the immunological system,
uremic patients on maintenance renal replacement therapy
are more susceptible to bacterial infections [9] and are at an
increased risk of developing cancer [10]. On the other
hand, circulating mononuclear cells from hemodialysis
patients show clear cut biological signs of activation, likely
caused by the combined action of activated complement
components, adherence to the dialysis membranes and
dialysate contaminants, such as endotoxins [11–13]. Grow-
ing interest has been recently focused on inflammatory
cytokine production as markers of leukocyte activation
and/or impaired function during hemodialysis [14, 15].
Evidence for increased plasma levels of different cytokines,
particularly for interleukin-6 (IL-6), monocyte chemotactic
peptide-1 (MCP-1) and IL-8, has been reported during
hemodialysis treatment [16–18]. In contrast, Pereira, Pout-
siaka and King [19] have shown a defect in IL-1 production
by peripheral blood mononuclear cells ( PBMC) from
undialyzed uremic patients or patients on peritoneal dial-
ysis, and a decreased IL-1 secretion in uremic monocytes
has also been reported by other authors [15, 20–22]. These
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observations have focused our interest on the regulation of
leukocyte function in hemodialysis patients, and led us to
investigate the mechanisms underlying the paradoxical
association between immune cell activation and biological
evidence of an aberrantly decreased immune response, and
to question whether the use of different dialytic membranes
may improve PBMC dysfunction. To address these issues,
the role of different hemodialysis membranes was evalu-
ated in regulating spontaneous PBMC gene expression and
protein synthesis of three different cytokines, IL-6, MCP-1
and IL-8, which could have a pathogenetic relevance in the
immune dysfunction of dialysis patients.
METHODS
Patients
Eight stable end-stage renal disease (ESRD) patients (4
males and 4 females, mean age 43.7 years, range 20 to 55
years), who had given their informed consent, were en-
rolled into the study. They had been stabilized on renal
replacement therapy for more than six months (mean
dialytic age 20.9 months; range 7 to 48 months) and were
undergoing chronic bicarbonate hemodialysis using cu-
prophan (CU) dialyzers for a mean time of 4.1 hours, three
times per week, when entering the study. The underlying
disease leading to end-stage renal failure was chronic
glomerulonephritis in five patients, chronic interstitial ne-
phropathy in one and polycystic kidney disease in two.
None of these patients had clinical evidence of infection at
the time of the study or took medication with immunosup-
pressive effect throughout the study. Two control groups
were also included in the study. The first control group
included eight uremic patients (5 males and 3 females,
mean age 42 years, range 18 to 62 years) on conservative
therapy. This group had serum creatinine of 789.4 6 108
mmol/liter and a creatinine clearance of 12.1 6 1.9 ml/min.
The diagnosis of the kidney disease was chronic glomeru-
lonephritis in four patients, chronic interstitial nephropathy
in three and polycystic kidney disease in one. The second
control group included eight healthy subjects (4 males and
4 females, mean age 28.1 years, range 21 to 40 years)
recruited from our laboratory personnel.
Study design
All ESRD patients underwent one month of standard
bicarbonate hemodialysis by using low-flux complement
activating CU membranes (membrane surface 1.22 m2,
Disscap 160 E; Hospal, Italy). Thereafter, six of them, in a
subsequent manner, switched for a month to high-flux
non-complement activating membranes, such as polymeth-
ylmethacrylate (PMMA; membrane surface 1.30 m2, Fil-
tryzer BK 1.3 U; Toray Industries, Tokyo, Japan) and
polyamide (PA; membrane surface 1.30 m2, Polyflux 130;
Gambro, Italy). Two of the original eight patients enrolled,
withdrew from the study after the first phase because of the
appearance of infection. Hemodialysis efficiency, as indi-
cated by pre- and post-treatment serum urea and the
weight loss over each dialysis session, remained unchanged
during the three study periods. Endotoxin content of the
dialysate, as shown by the colorimetric limulus amebocyte
lysate (LAL) assay (Coatest Kabi Vitrum, Sweden), was
less than 0.05 EU/ml and did not differ significantly during
the three study periods.
PBMC isolation and culture
After one month of treatment with CU, PMMA and PA,
blood samples (25 ml) were drawn in sterile heparinized
vacuum tubes from the patients’ arteriovenous fistulae at
the beginning (T0) and subsequently from the efferent line
of the dialyzer after 180 minutes (T180) of the dialysis
session. PBMC were isolated on a Ficoll/Hypaque gradient
(Pharmacia, Uppsala, Sweden). The mononuclear cell layer
was collected, washed twice with phosphate buffer saline
and resuspended in RPMI 1640 culture medium (Flow
Laboratories, Italy), supplemented with 25 mM Hepes
buffer, 2 mM L-glutamine, 100 IU/ml penicillin, 100 mg/ml
streptomycin and 2% heat-inactivated human AB serum as
previously described [13, 20]. The medium was filtered (U
2000; Gambro) prior to the use, to remove microbial
products. All solutions were endotoxin-free, as shown by
the colorimetric LAL assay (Coatest Kabi Vitrum). Finally,
1 ml aliquots (final concentration of 2 3 106 cells/ml) of the
cell suspension were added to culture tubes (Beckton
Dickinson, USA) and incubated for 6 or 24 hours at 37°C in
a 5% CO2 saturated humidity incubator. After incubation
for 24 hours at 37°C, supernatants were harvested and
stored at 280°C until used. Experiments were always
performed simultaneously on a dialyzed patient, a uremic
patient on conservative therapy and an apparently healthy
subject.
IL-6, MCP-1 and IL-8 concentrations in PBMC culture
supernatants were evaluated by enzyme-linked immunoab-
sorbent assay (ELISA) using commercially available kits
(Biotrack, Amersham, UK for IL-6 and IL-8; Quantikine,
R&D, UK for MCP-1). All samples and standards were
assayed in duplicate, and all samples for a given assay were
tested simultaneously. The sensitivity of the ELISA system
was 3 pg/ml for IL-6, 5 pg/ml for MCP-1 and 4.7 pg/ml for
IL-8.
Cytokine gene expression study
RNA extraction and reverse transcription-polymerase chain
reaction (RT-PCR). Total RNA was extracted from cul-
tured PBMC after six hours of incubation by the single-step
method [23] and then analyzed by gel electrophoresis. All
gels were stained with ethidium bromide to visualize 28S
and 18S ribosomal RNA bands and to exclude RNA
degradation. One microgram of total RNA was reverse-
transcribed into cDNA and then amplified by using the
Pertosa et al: Cytokine modulation by dialysis membranes 571
following sets of primers specific for IL-6, IL-8 and
GAPDH:
IL-6
sense: 59 -ATG AAC TCC TTC TCC ACA AGC GC- 39
antisense: 59 -GAA GAG CCC TCA GGC TGG ACT G- 39
IL-8
sense: 59 -ATG ACT TCC AAG CTG GCC GTG GCT- 39
antisense: 59 -TCT CAG CCC TCT TCA AAA ACT
TCT C- 39
MCP-1
sense: 59 -TTC TGT GCC TGC TGC TCA TA- 39
antisense: 59 -GAG TGA GTG TTC AAG TCT TCG- 39
GAPDH
sense: 59 -TGG TAT CGT GGA AGG ACT CAT GAC- 39
antisense: 59 -ATT CGT TGT CAT ACC AGG A- 39
Twenty microliters of reverse transcription-reaction mix-
ture, containing 1 mg of total RNA, PCR buffer (10 mM
Tris-HCl, pH 8.3, 50 mM KCl, 2.5 mM MgCl2), 1 mM dNTPs,
20 U of RNasin, 2.5 mM of oligo (dT) and 100 U of Moloney
murine leukemia virus (M-MLV) reverse transcriptase,
were incubated at 42°C for 30 minutes, heated to 95°C for
five minutes, and then quickly chilled on ice.
Polymerase chain reaction (PCR) was performed at a
final concentration of 1 3 PCR buffer, 200 mM dNTPs, 0.15
mM of each primer, 1.25 U of AmpliTaq DNA polymerase
(Perkin-Elmer, Roche Molecular System, NJ, USA), in a
total volume of 50 ml. The amplification profile involved
denaturation at 95°C for 30 seconds, primer annealing and
extension at 60°C for one minute. For semiquantitative
analysis, aliquots (10 ml) were taken after different num-
bers of cycles (20-25-30-40) to establish the amplification
plateau. Thirty cycles for IL-6 and IL-8 and 25 cycles for
GAPDH and MCP-1 resulted to be the best amplification
profile able to recognize differences among samples. Thus,
all samples were amplified and then electrophoresed on
1.5% agarose gels in Tris borate/EDTA buffer. Gels were
stained with ethidium bromide and photographed. The
bands obtained were quantified by densitometric analysis.
All signals obtained were normalized to the mRNA levels
of the housekeeping gene GAPDH and expressed as a
ratio.
Southern blotting. To confirm the specificity of IL-6 and
GAPDH PCR products, 1 ml of the amplified cDNA was
electrophoresed on 1.5% agarose gel, blotted onto a nylon
membrane (Schleicher & Schuell, Dassel, Germany) and
cross linked by exposure to UV light. After prehybridiza-
tion, the filter was hybridized with fluorescein labeled
cDNA probes (ECL Random prime labeling system, Am-
ersham, UK) specific for human IL-6 or GAPDH. Hybrid-
ization was performed at 60°C in 5 3 SSC, 0.1% SDS, 5%
dextran sulphate and denatured salmon sperm DNA (100
mg/ml). Thereafter, the filter was washed once in 1 3 SSC,
0.1% SDS and once in 0.5 3 SSC, 0.1% SDS at 60°C for 15
minutes each. Following the stringency washes, the filter
was blocked and incubated with horseradish peroxidase
conjugate anti-fluorescein antibody. The blot was then
covered with the detection buffer, containing luminol, and
exposed for three minutes to Kodak X-omat X-ray film.
In situ hybridization. MCP-1 gene expression in cultured
PBMC was also studied by in situ hybridization. To this
purpose, after six hours of culture, PBMC cytospins were
prepared onto polylisine-coated slides, dried briefly on a
hot plate (80°C) and fixed for 20 minutes in 4% parafor-
maldehyde. Cells were hybridized with either a MCP-1
antisense or a sense RNA probe, generated from a 200 bp
human MCP-1 cDNA template subcloned into the PCRII
vector. After linearization of the plasmid with either
BamHI or XbaI restriction endonucleases, T7 or SP6
RNA-polymerases (Boehringer Mannheim, Germany), re-
spectively, were employed to obtain run off transcripts of
either the antisense or sense strands. Transcription and
labeling of RNA probes was performed as previously
described [24]. Briefly, 80 mCi of [35S]uridine-59-(a-thio)-
triphosphate (specific activity 1,250 Ci/mmol; Amersham,
Little Chalfont, UK) was added to a 10 ml reaction mixture
(0.5 mM each of adenosine-, cytidine- and guanosine-59-
triphosphate/1 mM dithiothreitol/10 units human placental
RNase inhibitor/6 mM MgCl2/10 mM Tris-HCl, pH 7.5/2 mM
spermidine/10 mM NaCl) including 1 mg of linearized
plasmid and 16 units of either SP6 or T7 RNA polymerase.
The reaction was allowed to proceed for 60 minutes at
38°C. The plasmid DNA was removed by digestion with 25
mg/ml RNase-free DNase I in a mixture containing 15
mg/ml of yeast tRNA and 10 units of RNase inhibitor for 10
minutes at 37°C. Free ribonucleotides were removed by
phenol/chloroform extraction followed by ethanol precipi-
tation. RNA probes were then diluted in hybridization
buffer, stored at 280°C and used within four weeks. The
specific activity usually obtained was 1.2 to 1.4 3 109
cpm/mg of 35S-labeled RNA probe.
Prehybridization, hybridization, removal of nonspecifi-
cally bound probe by RNase A digestion, and further
washing procedures were performed for both sense and
antisense MCP-1 RNA probe as described previously [24].
Autoradiography was performed by dipping the dehydrated
slides into Ilford G5 nuclear emulsion (Ilford, Mobberley
Cheshire, UK) and subsequent development was per-
formed with Kodak D19 developer (Kodak, Hemel Hamp-
stead, UK). Finally, slides were counterstained with hema-
toxylin.
Statistical analysis
All results have been given as means 6 SEM (X 6 SEM).
Significance was assessed using the paired or unpaired
Student’s t-test, as appropriate. Differences were consid-
ered to be significant when P , 0.05.
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RESULTS
Effect of hemodialysis membranes on cytokine
production
Figure 1 depicts the spontaneous production of IL-6
(Fig. 1A), IL-8 (Fig. 1B) and MCP-1 (Fig. 1C) from PBMC
of normal subjects and uremic patients on conservative
therapy. After 24 hours of culture in the presence of human
AB serum, the secretion of all three cytokines was reduced
in the supernatant of PBMC from uremic patients on
conservative therapy compared to those from normal sub-
jects, although only for MCP-1 and IL-8 did the difference
reach a statistical significance (P , 0.05 and P , 0.01,
respectively).
We then evaluated the effects of hemodialysis treatment
with different membranes on IL-6, IL-8 and MCP-1 pro-
duction by PBMC cultured in the presence of human AB
serum. To this purpose uremic patients were dialyzed
subsequently for one month with CU, PMMA and PA, and
cytokine production was evaluated in the supernatant of
PBMC isolated at T0 and T180 of a dialysis session at the
end of each study period. The IL-6, IL-8 and MCP-1
protein concentrations in PBMC supernatants were mark-
edly lower in uremic patients after one month of treatment
with low-flux CU membrane, compared to normal subjects
(Figs. 2A, 3A and 4A). The reduction was evident both at
TO and at T180.
One month of treatment with PMMA membrane nor-
malized both pre-dialysis as well as post-dialysis IL-6, IL-8
and MCP-1 secretion (Figs. 2A, 3A and 4A). The subse-
quent month of treatment with PA induced a further
increase of cytokines secretion, particularly for IL-6 and
MCP-1 (Figs. 2A, 3A and 4A). The IL-6, MCP-1 and IL-8
PBMC production at T0 for every patient included in the
study is shown in Figures 2B, 3B and 4B, respectively.
Effect of hemodialysis membranes on cytokine
transcription
To determine if the changes in cytokines secretion were
due to an altered transcription, we used RT-PCR to study
the IL-6, IL-8 and MCP-1 gene expression in cultured
PBMC obtained from normal subjects, uremic patients on
conservative therapy and dialyzed patients after the three
different treatments. We first evaluated IL-6 mRNA levels.
The control group and the uremic patients on conservative
therapy showed an equal expression of this cytokine (Fig.
5). Surprisingly, despite the reduction in spontaneous IL-6
secretion by PBMC, a significant increase of mRNA ex-
pression was observed in the uremic patients treated by CU
as compared to normal subjects (Fig. 5). By contrast, the
use of PMMA or PA membranes for one month deter-
mined a reduction of IL-6 gene expression as compared to
CU-treated patients (Fig. 5). The mRNA abundance for
this cytokine after two months of dialysis with non-comple-
ment activating membranes were comparable with the level
of the control group. The IL-8 and MCP-1 mRNA expres-
sion resembled the pattern described for IL-6 with an
increased gene expression in uremic patients treated with
Fig. 1. Spontaneous production of IL-6 (A), IL-8 (B) and MCP-1 (C)
from PBMC of normal subjects and uremic patients on conservative
therapy. Cytokine release, particularly IL-8 and MCP-1, was reduced in
the uremic group compared to the healthy subjects. *P , 0.05 and **P ,
0.01 versus normal subjects.
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CU as compared to controls (Figs. 6 and 7). The use of
PMMA and PA for one month determined a reduced
mRNA expression of these chemokines at T0 as well as at
T180 as compared to CU-treated patients (Figs. 6 and 7).
After the month of dialysis with PA the expression was
significantly lower than in the control group. The MCP-1
mRNA levels were also evaluated by in situ hybridization,
confirming the pattern of expression observed by RT-PCR
(Fig. 8). Moreover, the in situ hybridization technique
allowed us to identify the monocytes, present in the PBMC,
as the main cell population expressing this chemokine (Fig.
8).
DISCUSSION
The mechanisms underlying the paradoxical association
of leukocyte activation and defective immune response in
ESRD patients undergoing chronic hemodialysis are still
largely unclear. A growing body of evidence suggests that
cytokines may represent the main regulators of leukocyte
functions [14, 25]. Indeed, each of these soluble mediators
may act on leukocytes, in synergism or in antagonism with
Fig. 2. (A) Spontaneous production of IL-6 from PBMC of normal
subjects (N) and uremic patients before (T0; f) and after (T180; u)
dialysis with different membranes. (B) IL-6 production from PBMC at T0
in any single patient included in the study; spontaneous production in
normal subjects (N) is shown as mean 6 SEM. **P , 0.01 versus normal
controls. Abbreviations are: CU, cuprophan; PMMA, polymethylmetac-
rylate; PA, polyamide.
Fig. 3. (A) Spontaneous production of IL-8 from PBMC of normal
subjects (N) and uremic patients before (T0; f) and after (T180; u)
dialysis with different membranes. (B) IL-8 production from PBMC at T0
in any single patient included in the study; spontaneous production in
normal subjects (N) is shown as mean 6 SEM. **P , 0.01 versus normal
subjects. Abbreviations are: CU, cuprophan; PMMA, polymethylmetacry-
late; PA, polyamide.
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each other, modulating chemotaxis, phagocytosis, immuno-
globulin production, and their own gene and protein ex-
pression [25]. These findings have led several investigators
to study the plasmatic levels of various pro-inflammatory
cytokines in hemodialysis patients. However, controversial
results have been reported. Indeed, while several authors
observed a significant increase in IL-1, IL-6, TNF-a, IL-8
and MCP-1 plasma levels [16–18, 26], others have found no
difference or, surprisingly, a reduction [15]. Moreover,
evidence for the induction of these cytokines in cultured
PBMC has been reported during hemodialysis treatment,
likely due to the combined action of activated complement
components, adherence to the membranes and interaction
with dialysate contaminants, such as endotoxins [17, 27, 28].
By contrast, some authors have reported an impaired
endotoxin-induced IL-1, TNFa and IL-6 release from
PBMC of hemodialysis patients, suggesting a reduced
ability of the immune cells of these patients to respond to
pathologic stimuli [19, 20, 29].
In the attempt to clarify the controversial findings on
PBMC dysfunction and activation, we evaluated the role of
Fig. 4. (A) Spontaneous production of MCP-1 from PBMC of normal
subjects and uremic patients before (T0; f) and after (T180; u) dialysis
with different membranes. (B) MCP-1 production from PBMC at T0 in
any single patient included in the study; spontaneous production in normal
subjects (N) is shown as mean 6 SEM. **P , 0.01 versus normal subjects.
Abbreviations are: CU, cuprophan; PMMA, polymethylmetacrylate; PA,
polyamide.
Fig. 5. (A) IL-6 (upper panel) and GAPDH (lower panel) gene expression
by PBMC during hemodialysis with different membranes, studied by
RT-PCR and Southern blotting as described in the Methods section (a
representative gel is shown). (B) An increase of IL-6 mRNA expression
was observed in uremic patients treated with CU as compared to normal
subjects (N) and non-dialyzed uremic patients (U). Symbols are: (f) T0,
before dialysis; (M) T180, after dialysis. By contrast, the use of non-
complement activating membranes, such as PMMA and PA, determined a
reduced expression of IL-6 mRNA in pre-HD (T0) PBMC as compared to
CU-treated patients.*P , 0.05 versus normal subjects; **P , 0.05 versus
CU T0. Abbreviations are: CU, cuprophan; PMMA, polymethylmetacry-
late; PA, polyamide.
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different hemodialysis membranes in regulating spontane-
ous IL-6, IL-8 and MCP-1 gene expression and protein
synthesis by PBMC isolated from chronic hemodialyzed
patients. All of these cytokines could have a pathogenetic
relevance in the immune dysfunction of dialysis patients,
given their modulatory effect on monocyte, granulocyte, T
and B cell activation [30–32]. Interestingly, our data dem-
onstrate, for the first time, the independent modulation of
cytokines gene expression and protein secretion in un-
stimulated PBMC by different hemodialysis membranes.
Indeed, the transcriptional activation of these cytokines
occurs in unstimulated PBMC following the use of cellulo-
sic membranes, whereas their protein synthesis is seemingly
impaired. By contrast, long-term hemodialysis with syn-
thetic high-flux membranes, such as PMMA and PA,
down-regulates cytokine gene expression and improves the
ability of PBMC to secrete cytokines in culture. Our
observations suggest that PBMC isolated from patients
undergoing chronic hemodialysis present an activated phe-
notype as demonstrated by the striking up-regulation of
cytokine gene expression. However, they are unable to
synthesize and secrete the same cytokines; this impaired
Fig. 6. (A) IL-8 (upper panel) and GAPDH (lower panel) gene expression
by PBMC during hemodialysis with different membranes, studied by
RT-PCR as described in the Methods section (a representative gel is
shown). (B) An increase in IL-8 transcripts was observed in uremic
patients treated with CU membranes, as compared to normal subjects (N)
and non-dialyzed uremic patients (U). By contrast, the use of biocompat-
ible membranes (PMMA and PA) determined a decrease in IL-8 mRNA
levels. *P , 0.05 versus normal subjects; **P , 0.05 versus CU T0.
Abbreviations are: CU, cuprophan; PMMA, polymethylmetacrylate; PA,
polyamide.
Fig. 7. (A) MCP-1 (upper panel) and GAPDH (lower panel) gene expres-
sion by PBMC during hemodialysis with different membranes, studied by
RT-PCR as described in the Methods section (a representative gel is
shown). (B) An increase in MCP-1 transcripts was observed in uremic
patients treated with CU membranes, as compared to normal subjects (N)
and non-dialyzed uremic patients (U). By contrast, the use of biocompat-
ible membranes (PMMA and PA) determined a decrease in MCP-1
mRNA levels. *P , 0.05 versus normal subjects; **P , 0.05 versus CU T0.
Abbreviations are: CU, cuprophan; PMMA, polymethylmetacrylate; PA,
polyamide.
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Fig. 8. MCP-1 gene expression in PBMC of controls and hemodialysis patients treated with different membranes. MCP-1 gene expression was studied
by in situ hybridization as described in the Methods section. Bright (A, C, E and G) and dark (B, D, F and H) field photomicrographs of PBMC isolated
from healthy subjects (A and B) and at T0 from patients treated by CU (C and D), PMMA (E and F) and PA (G and H) membranes. CU treatment
induces a clear upregulation of MCP-1 mRNA whereas the treatment with non-complement activating membranes reduces it.
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ability could, at least partially, explain the altered immune
system function in hemodialysis patients.
A variety of factors may contribute to the decrease in
cytokine production observed during bioincompatible he-
modialysis in the presence of an increased gene expression
for the same cytokine. Thus, several hypotheses have been
proposed. The first is represented by intracellular depletion
due to cytokine release in vivo. Indeed, once activated by
the contact with the dialysis membrane the leukocytes
return into the circulation, and can then synthesize and
release the cytokines [16–18, 33]. According to this hypoth-
esis the PBMC collected could be exhausted and not able to
promote any further protein synthesis. Although the acute
exhaustion can be ruled out in our study, since a reduced
secretion was observed even at the beginning of the dialysis
session, we cannot exclude the long-term exhaustion of
mononuclear cells chronically exposed to the activating
stimulus. The second hypothesis is represented by the
concomitant secretion of cytokine-specific binding proteins.
Several investigators have studied plasma levels of cyto-
kine-specific inhibitory proteins, such as IL-1 receptor
antagonist and TNF soluble receptor. In hemodialysis
patients the circulating levels of these proteins are several-
fold higher than IL-1 and TNF-a [34]. Moreover, in
cultured PBMC from hemodialysis patients the production
of cytokine-specific binding proteins is significantly higher
than that of their pro-inflammatory counterparts [34]. If an
IL-6-specific inhibitory protein has been described, no such
protein is known for IL-8 and MCP-1 [35]. Moreover, what
makes the “soluble-antagonist hypothesis” less likely in our
study is that three completely different cytokines showed
the identical pattern of secretion. According to a third
hypothesis, leukocyte-membrane contact as well as acti-
vated complement fractions generated by the blood-mem-
brane interaction, although able to induce a selective
cytokine mRNA transcription, do not stimulate the trans-
lation of their specific proteins. Indeed, Schindler et al have
demonstrated that recombinant C5a stimulates transcrip-
tion rather than translation of IL-1, and that LPS or IL-1
itself is required as a translational signal [11]. In support to
these hypothesis, we have recently shown that the basal
release of TNF-a and IL-6 during hemodialysis is consid-
erably influenced by the endotoxin content of the bicarbon-
ate concentrate as well as the type of membrane used [13].
Finally, chronic use of CU may contribute to the dysregu-
lation of the translational and/or post-translational pro-
cesses, thus explaining the apparent dissociation between
cytokine mRNA expression and protein release.
Nevertheless, we can speculate that, if the increased
cytokine gene expression could be considered as a marker
of leukocyte activation and of membrane biocompatibility,
during bioincompatible dialytic treatment the reduced cy-
tokine secretion might play a key role in the pathogenesis
of the immune deficiency present in dialyzed patient.
Finally, the normal responses observed following exposure
to non-complement activating membranes, such as PMMA
and PA, support the recurrent activation of complement as
a pivotal pathogenetic factor in the changes observed in
cytokine gene expression and protein synthesis. In conclu-
sion, our study suggests a central role of the dialyzers in the
dialysis-associated immune system dysregulation. Thus, a
better understanding of the interactions between leuko-
cytes and the synthetic surface of the membrane may help
in designing new dialysis filters and in optimizing hemodi-
alysis treatments.
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APPENDIX
Abbreviations used in this article are: CU, cuprophan; ELISA, enzyme-
linked immunoabsorbent assay; ESRD, end-stage renal disease; IL, inter-
leukin; LAL, limulus amebocyte lysate; MCP-1, monocyte chemotactic
peptide-1; PA, polyamide; M-MLV, Maloney murine leukemia virus;
PBMC, peripheral blood mononuclear cells; PCR, polymerase chain
reaction; PMMA, polymethylmethacrylate; T0, beginning of dialysis;
T180, post-dialysis; TNF-a, tumor necrosis factor-alpha.
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